These proof of principle studies emphasize the superiority of [<sup>18</sup>F]DASA-23 to [<sup>18</sup>F]FDG in detecting the glycolytic response of GBM to multiple classes of anti-neoplastic drugs in cell culture.
Subsequently, 2-[<sup>18</sup>F]FELP was assessed in vivo and compared with [<sup>18</sup>F]FET and [<sup>18</sup>F]FDG in a F98 glioblastoma rat model.
The aim of this study was to evaluate positron emission tomography (PET) imaging with [<sup>68</sup>Ga]NODAGA-c(RGDfK) ([<sup>68</sup>Ga]RGD), in comparison with 2-deoxy-2-[<sup>18</sup>F]fluoro-D-glucose ([<sup>18</sup>F]FDG), for early monitoring of the efficacy of an antiangiogenic agent associated or not with chemotherapy, in a mouse model of glioblastoma (GB).
Therefore, inter-model comparisons showed significantly divergent responses (p < 0.01) of [<sup>18</sup>F]FDB between lymphoma and GBM, while [<sup>18</sup>F]FDG demonstrated overlap (p = 0.04) between the groups.